+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Drug Eluting Balloon Market by Application, Drug Type, End User, Product Type, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896654
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Drug Eluting Balloon Market grew from USD 1.09 billion in 2024 to USD 1.27 billion in 2025. It is expected to continue growing at a CAGR of 15.84%, reaching USD 2.65 billion by 2030.

Unveiling the Strategic Significance of Drug Eluting Balloons

Drug eluting balloons have rapidly emerged as a pivotal innovation in interventional cardiology and vascular therapy, combining the mechanical benefit of angioplasty with targeted drug delivery to inhibit restenosis. Clinicians worldwide increasingly recognize the value of these devices in treating complex coronary artery disease as well as peripheral artery disease, leading to an expanding role in both first-line interventions and cases where previous stenting has failed. The introduction of drug eluting balloons marks a paradigm shift from permanent implants toward temporary, localized drug application that reduces neointimal proliferation without leaving a scaffold behind.

Within this advanced therapeutic category, ongoing refinements in balloon design, coating technologies and catheter delivery systems have addressed early concerns around uniform drug transfer and drug loss during delivery. Regulatory approvals across multiple jurisdictions now validate the safety profiles established in extensive clinical trials, driving physician confidence and payer acceptance. Concurrently, growing patient awareness of minimally invasive options is fueling demand for interventions that minimize complications and shorten hospital stays.

Stakeholders across healthcare are evaluating not only clinical efficacy but also economic value, as health systems seek to balance upfront device costs with long-term reductions in repeat interventions. Real-world data demonstrating lower rates of target lesion revascularization have strengthened the case for adoption, particularly in patient populations with high comorbidity burdens. Meanwhile, competition from drug coated balloons and emerging bioresorbable scaffolds has intensified the imperative for ongoing innovation. Against this backdrop, industry and clinical leaders are collaborating to refine procedural protocols, optimize lesion preparation techniques, and enhance drug formulations to maximize therapeutic outcomes.

This summary distills those multi-faceted developments into strategic insights that will inform decision making at executive and clinical leadership levels. It serves as a blueprint for understanding where the drug eluting balloon market stands today and where it is headed in a dynamic healthcare environment.

Emerging Forces Reshaping the Drug Eluting Balloon Arena

Over the past few years, several transformative shifts have converged to redefine the drug eluting balloon landscape. Advances in drug coating technology, for instance, have refined polymer matrices to achieve more consistent release profiles, while novel antiproliferative agents beyond paclitaxel have entered development pipelines. Such innovations have expanded treatment possibilities from simple focal lesions to more challenging diffuse and calcified arterial segments, fostering broader clinical adoption.

In parallel, evolving evidence from large-scale registries and randomized trials has illuminated optimal procedural approaches, highlighting the critical role of lesion preparation and imaging guidance in maximizing drug transfer efficiency. As a result, interventionalists are increasingly integrating intravascular ultrasound and optical coherence tomography to tailor treatments, reducing variability in patient outcomes and bolstering confidence among referring physicians.

Furthermore, shifts in healthcare policy and reimbursement models are accelerating adoption of value-based payment schemes that reward durable results over multiple interventions. Payers in several markets now consider total episode cost, incentivizing technologies that demonstrate sustained efficacy. Coupled with a growing emphasis on same-day discharge pathways, particularly in ambulatory surgical settings, this trend underscores the importance of devices that reduce complication rates and shorten recovery times.

Simultaneously, globalization of clinical research has democratized access to cutting-edge therapies, with emerging markets embracing drug eluting balloons in peripheral arterial disease management. Collaborative efforts between academic centers, industry partners and regulators have streamlined approval pathways, enabling faster patient access and generating real-world safety data that further reinforce market growth. Collectively, these forces are converging to propel the next phase of innovation and adoption in the drug eluting balloon sector.

Assessing How 2025 Tariffs Redefine Domestic Access and Costs

Imminent tariff adjustments slated for 2025 are poised to exert significant influence on the cost structure and supply chain dynamics of drug eluting balloons. By imposing higher duties on imported components and finished devices, these measures will raise entry barriers for manufacturers reliant on offshore production. Such a policy shift stands to impact device pricing, as increased import costs could translate into higher procedural expenses and pressure on hospital budgets.

Manufacturers are responding by evaluating options for expanding in-country production capabilities or restructuring global supply networks to mitigate tariff exposure. Strategic partnerships between device companies and domestic contract manufacturers have already begun to form, aiming to localize critical processes such as catheter assembly and balloon coating. These collaborations not only address policy-induced cost challenges but also enhance supply resilience in the face of potential trade disruptions.

Health systems may face difficult decisions in balancing budget constraints with clinical needs. To contain operating expenses, procurement teams are intensifying negotiations for volume-based pricing, while clinicians advocate for targeted use in high-risk patient cohorts most likely to benefit. In certain regions, payers are revisiting coverage policies, requiring more robust real-world evidence to justify premium pricing for drug eluting balloons over conventional angioplasty solutions.

Despite the near-term uncertainty, the tariff landscape also presents opportunity. By fostering domestic manufacturing capacity, stakeholders can reduce lead times, improve quality control and potentially capitalize on export markets exempt from external duties. Ultimately, proactive adaptation along the value chain will prove essential to sustaining growth and ensuring patient access to this critical technology under the new trade regime.

Decoding Market Segments for Precision Growth Strategies

The drug eluting balloon market exhibits distinct nuances across clinical applications, with coronary and peripheral arterial domains each presenting unique growth trajectories. Within the coronary artery disease space, practitioners navigate both first-time interventions for native de novo lesions and complex scenarios involving in-stent restenosis, where balloon-mediated drug release offers a scaffold-free alternative to treat tissue proliferation within an existing stent framework. In peripheral artery interventions, treatment of lesions below the knee demands devices engineered for smaller vessels and challenging branch anatomies, while femoropopliteal procedures call for balloons capable of sustained drug delivery in longer segments exposed to flexion.

Drug formulation further defines competitive positioning, as products coated with paclitaxel leverage a well-established antiproliferative profile, whereas offerings utilizing sirolimus introduce a newer therapeutic modality with potential for improved long-term vessel patency. Each drug type requires specific carrier matrices to facilitate optimal transfer during brief balloon inflation, giving rise to differentiated product pipelines and patent strategies.

End-user channels shape deployment patterns, too. In the ambulatory surgical center environment, adoption is driven by a focus on rapid turnover and outpatient protocols, whereas clinics emphasize cost efficiency and ease of use for lower-risk lesions. Hospitals remain the core setting for high-complexity cases, supported by comprehensive imaging suites and multidisciplinary teams.

Product architectures also vary, contrasting conventional angioplasty balloons with specialty designs that incorporate features such as semi-compliant materials, scoring wires or dual-layer coatings to optimize drug retention and lesion apposition. Finally, distribution frameworks split between direct partnerships and third-party distributors reflect differences in service capabilities, from dedicated field support to integrated supply chain management. Recognizing these interwoven dimensions enables companies to tailor go-to-market strategies, prioritize R&D investments and align pricing models with the specific demands of each segment.

Regional Variations Driving Adoption and Innovation

Geographic markets for drug eluting balloons exhibit diverse regulatory, clinical and economic characteristics that influence uptake. In the Americas, market maturity is anchored by well-established regulatory pathways and reimbursement frameworks that reward devices demonstrating superior long-term outcomes. Clinician consensus around lesion preparation protocols and robust registry data have accelerated integration into both coronary and peripheral interventions, while a competitive insurance landscape incentivizes providers to adopt innovations that reduce repeat procedures.

Across Europe, Middle East and Africa, heterogeneity in health system financing and regulatory rigor creates a patchwork of opportunities. In Western Europe, centralized procurement and health technology assessments drive high-value purchases, often favoring the latest generation of polymer-free drug eluting balloons with extensive clinical validation. In contrast, emerging Middle Eastern markets balance cost considerations with a desire to adopt premium therapies, fostering partnerships between local distributors and global manufacturers. African regions, though currently in early stages, show potential as infrastructure investments expand access to minimally invasive vascular therapies.

Asia-Pacific markets present significant growth potential driven by escalating cardiovascular disease prevalence and expanding healthcare infrastructure. High-income economies such as Japan and Australia follow stringent regulatory regimes that mirror Western standards, whereas fast-growing markets in Southeast Asia and India are streamlining approval processes to attract investment. These regions demonstrate strong demand for cost-effective yet efficacious treatments, prompting manufacturers to explore innovative pricing models and licensing agreements with local partners to achieve scale.

Understanding these regional dynamics is critical for designing targeted market entry plans, aligning clinical and regulatory affairs strategies, and customizing value propositions to address the specific needs of each territory.

Competitive Landscape: Pioneers Advancing Device Efficacy and Access

Industry leaders are spearheading innovation in drug eluting balloon development through strategic collaborations, targeted acquisitions and ongoing investment in R&D. Established medical device companies continue to refine proprietary coating technologies, leveraging decades of clinical experience in antiproliferative drug use. These incumbents focus on expanding their portfolios across both paclitaxel and sirolimus formulations, while integrating advanced delivery catheters that improve lesion site conformity and reduce procedural complexity.

In parallel, emerging specialist firms are carving out niches by developing polymer-free balloons and next-generation carrier matrices that promise enhanced drug retention with reduced inflammatory risk. Such nimble players often partner with academic centers to conduct investigator-led trials, generating evidence that supports premium positioning and accelerates regulatory approvals. Venture-backed companies also explore novel agents beyond traditional cytostatic compounds, investigating anti-inflammatory or angiogenic molecules to address unmet clinical needs in complex lesions.

Beyond technological innovation, competitive differentiation arises through service offerings. Some manufacturers provide on-site training programs and case support, enabling interventional teams to adopt best practices in lesion preparation and drug delivery. Others emphasize integrated solutions that combine device supply with data analytics platforms, giving providers clearer visibility into procedural outcomes and cost-effectiveness metrics.

Mergers and acquisitions continue to shape the market, as larger entities absorb smaller innovators to broaden their product portfolios and geographic reach. Strategic alliances between device companies and contract manufacturers facilitate rapid scale-up of production while maintaining quality standards. Together, these dynamics create a vibrant competitive ecosystem in which both global players and specialized entrants drive progress, ultimately expanding patient access to advanced vascular therapies.

Strategic Imperatives for Industry Leaders to Seize Emerging Opportunities

In light of evolving market dynamics, industry leaders must adopt a multifaceted strategy to maintain a competitive edge. Prioritizing innovation in drug formulation and balloon design will be essential, with a focus on developing carrier matrices that maximize drug transfer efficiency while minimizing vascular irritation. By accelerating clinical research on sirolimus-coated and alternative therapeutic agents, companies can differentiate their pipelines and address emerging clinical demands.

To mitigate the impact of shifting trade policies, expanding domestic manufacturing capacity emerges as a critical priority. Establishing localized production hubs not only reduces tariff exposure but also shortens supply chains, enhancing responsiveness to market fluctuations. Collaborative ventures with regional contract manufacturers and strategic insurers can further reinforce supply resilience and align pricing with local reimbursement frameworks.

Engaging key opinion leaders and early adopter clinicians is equally vital. By hosting hands-on training workshops and sharing real-world evidence, device companies can drive consensus on optimal procedural protocols and foster peer-to-peer learning. Integrating digital platforms that deliver procedural analytics and patient outcome tracking will bolster value propositions in negotiations with health systems and payers.

Finally, pursuing agile market entry strategies in high-growth territories requires tailored regulatory and commercial models. Adaptive pricing agreements and risk-sharing contracts can facilitate adoption in both mature and emerging markets, while dedicated distribution partnerships ensure efficient product availability. Through this integrated approach-fusing technological leadership, supply chain agility and stakeholder engagement-industry participants can capture new growth avenues and solidify their positions in the rapidly evolving drug eluting balloon market.

Robust Research Framework Underpinning the Analysis

The findings presented in this executive summary derive from a comprehensive research framework combining primary and secondary data sources. Our methodology began with in-depth interviews conducted with leading interventional cardiologists, vascular surgeons and healthcare procurement specialists, providing firsthand perspectives on clinical preferences, procedural trends and purchasing behaviors. These qualitative insights were complemented by rigorous secondary research, including analysis of regulatory filings, peer-reviewed clinical trial data and health technology assessment reports from major global agencies.

To ensure accuracy and relevancy, proprietary databases were leveraged to track device approvals, patent filings and corporate transactions. Real-world performance metrics were validated through large-scale procedural registries, while peer comparisons were drawn from global sales data aggregated across key markets. We applied triangulation techniques to reconcile discrepancies and enhance data reliability.

Segmentation analyses examined clinical application categories, drug formulations, end-user environments, product architectures and distribution channels, ensuring a holistic understanding of market nuances. Regional assessments incorporated macroeconomic indicators, regulatory frameworks and health system characteristics to capture geographic variations. Competitive intelligence was enriched through financial disclosures, strategic announcements and patent portfolio reviews.

Throughout the research process, quality control protocols were enforced, including cross-review by subject matter experts and iterative feedback loops with industry stakeholders. This robust approach underpins the strategic insights and recommendations articulated herein, equipping decision-makers with a validated foundation for shaping future initiatives in the drug eluting balloon domain.

Synthesizing Insights to Guide Future Decision Making

Bringing together the diverse strands of analysis, the current landscape of drug eluting balloon technology reflects a dynamic interplay of clinical innovation, economic pressures and regulatory evolution. Advanced coating formulations and refined delivery systems are driving expanded use across coronary and peripheral arterial applications, while emerging evidence continues to shape best practices in lesion preparation and procedural guidance. Evolving tariff regimes are prompting manufacturers to reassess supply chain strategies, underscoring the importance of localized production and adaptable commercial models.

Segmentation insights reveal that each clinical application and end-user setting demands tailored product features and engagement approaches, necessitating precise alignment of R&D priorities with market requirements. Regional variations further emphasize the need for customized regulatory and reimbursement strategies, as health systems in different geographies operate under distinct policy frameworks and budgetary constraints. Competitive pressures are intensifying, with both established medical device leaders and innovative startups accelerating product development and forging strategic alliances to capture share.

Against this backdrop, the recommendations outlined herein serve as strategic imperatives to navigate the near-term challenges and seize long-term growth opportunities. By embracing technological differentiation, reinforcing supply chain resilience and cultivating stakeholder partnerships, industry participants can position themselves at the forefront of this rapidly evolving market. The path forward demands agility, collaboration and a relentless focus on generating clinical and economic value to support sustainable innovation in vascular care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Coronary Artery Disease
      • De Novo Lesion
      • In-Stent Restenosis
    • Peripheral Artery Disease
      • Below Knee
      • Femoropopliteal
  • Drug Type
    • Paclitaxel-Coated
    • Sirolimus-Coated
  • End User
    • Ambulatory Surgical Center
    • Clinic
    • Hospital
  • Product Type
    • Conventional Balloon
    • Specialty Balloon
  • Distribution Channel
    • Direct
    • Distributor
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Medtronic plc
  • Boston Scientific Corporation
  • B. Braun SE
  • Koninklijke Philips N.V.
  • Becton Dickinson and Company
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Cook Medical LLC
  • Elixir Medical Corporation
  • Concept Medical Research Private Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drug Eluting Balloon Market, by Application
8.1. Introduction
8.2. Coronary Artery Disease
8.2.1. De Novo Lesion
8.2.2. in-Stent Restenosis
8.3. Peripheral Artery Disease
8.3.1. Below Knee
8.3.2. Femoropopliteal
9. Drug Eluting Balloon Market, by Drug Type
9.1. Introduction
9.2. Paclitaxel-Coated
9.3. Sirolimus-Coated
10. Drug Eluting Balloon Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Center
10.3. Clinic
10.4. Hospital
11. Drug Eluting Balloon Market, by Product Type
11.1. Introduction
11.2. Conventional Balloon
11.3. Specialty Balloon
12. Drug Eluting Balloon Market, by Distribution Channel
12.1. Introduction
12.2. Direct
12.3. Distributor
13. Americas Drug Eluting Balloon Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Drug Eluting Balloon Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Drug Eluting Balloon Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Medtronic plc
16.3.2. Boston Scientific Corporation
16.3.3. B. Braun SE
16.3.4. Koninklijke Philips N.V.
16.3.5. Becton Dickinson and Company
16.3.6. Terumo Corporation
16.3.7. MicroPort Scientific Corporation
16.3.8. Cook Medical LLC
16.3.9. Elixir Medical Corporation
16.3.10. Concept Medical Research Private Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DRUG ELUTING BALLOON MARKET MULTI-CURRENCY
FIGURE 2. DRUG ELUTING BALLOON MARKET MULTI-LANGUAGE
FIGURE 3. DRUG ELUTING BALLOON MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DRUG ELUTING BALLOON MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DRUG ELUTING BALLOON MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUG ELUTING BALLOON MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY BELOW KNEE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL-COATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS-COATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY CONVENTIONAL BALLOON, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY SPECIALTY BALLOON, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DIRECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 46. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 47. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 50. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 89. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 90. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 97. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 103. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 110. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 111. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 117. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 118. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 119. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. UNITED ARAB EMIRATES DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 124. UNITED ARAB EMIRATES DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 125. UNITED ARAB EMIRATES DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 132. SAUDI ARABIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. SOUTH AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. SOUTH AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 138. SOUTH AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 139. SOUTH AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. DENMARK DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. DENMARK DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 145. DENMARK DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 146. DENMARK DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 147. DENMARK DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. DENMARK DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 149. DENMARK DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. NETHERLANDS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. NETHERLANDS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 152. NETHERLANDS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 153. NETHERLANDS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. QATAR DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. QATAR DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 159. QATAR DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 160. QATAR DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 161. QATAR DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. QATAR DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. QATAR DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. FINLAND DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. FINLAND DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 166. FINLAND DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 167. FINLAND DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. FINLAND DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. FINLAND DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 170. FINLAND DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. EGYPT DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. EGYPT DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 187. EGYPT DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 188. EGYPT DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 189. EGYPT DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. EGYPT DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. EGYPT DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. TURKEY DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. TURKEY DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 194. TURKEY DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 195. TURKEY DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 196. TURKEY DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. TURKEY DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. TURKEY DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. ISRAEL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. ISRAEL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 201. ISRAEL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 202. ISRAEL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. NORWAY DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. NORWAY DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 208. NORWAY DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 209. NORWAY DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 210. NORWAY DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NORWAY DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. NORWAY DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. POLAND DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. POLAND DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 215. POLAND DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 216. POLAND DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. POLAND DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. POLAND DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. POLAND DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 235. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 237. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 238. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 239. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 244. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 245. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 246. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 250. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 251. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 252. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 253. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 265. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. THAILAND DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. THAILAND DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 279. THAILAND DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 280. THAILAND DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 281. THAILAND DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. THAILAND DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. THAILAND DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. MALAYSIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. MALAYSIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 293. MALAYSIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. SINGAPORE DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. SINGAPORE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 300. SINGAPORE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 301. SINGAPORE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. VIETNAM DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 306. VIETNAM DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 307. VIETNAM DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 308. VIETNAM DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 309. VIETNAM DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. VIETNAM DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 312. TAIWAN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 313. TAIWAN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 314. TAIWAN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 315. TAIWAN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 316. TAIWAN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. TAIWAN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 318. TAIWAN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. DRUG ELUTING BALLOON MARKET SHARE, BY KEY PLAYER, 2024
TABLE 320. DRUG ELUTING BALLOON MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Drug Eluting Balloon market report include:
  • Medtronic plc
  • Boston Scientific Corporation
  • B. Braun SE
  • Koninklijke Philips N.V.
  • Becton Dickinson and Company
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Cook Medical LLC
  • Elixir Medical Corporation
  • Concept Medical Research Private Limited

Methodology

Loading
LOADING...

Table Information